Discovery of the small molecular inhibitors against TRPV6 as potential anti-cancer agents by structural based virtual screening
Lixuan Wang, Xin Deng, Ruoyang Hu, Shuguang Tan, Lin Zhang, Mingqiang Rong, Liqing Hu, Xing Feng, Hui Zou, Junbo Wu · 2026
Read Discovery of the small molecular inhibitors against TRPV6 as potential anti-cancer agents by structural based virtual screening by Lixuan Wang, Xin Deng, Ruoyang Hu, Shuguang Tan, Lin Zhang, Mingqiang Rong, Liqing Hu, Xing Feng, Hui Zou, Junbo Wu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13457706.txt.
Description
Lixuan Wang and colleagues go fishing for a blocker of TRPV6, a calcium channel that several cancers exploit to grow and spread. Known blockers lack selectivity and hit off-targets, so the team screened compound libraries in the computer against the channel's structure. Their 2026 study lands on a candidate named AZ191 and moves it into electrical and cell-based testing.
Patch measurements put AZ191's potency against human TRPV6 at an IC50 of 3.83 micromolar, a strong showing for an early lead. In culture, the compound's anti-tumor effects tracked with its blockade of the channel, supporting the idea that shutting this calcium gateway can slow cancer cells. The authors offer AZ191 as a starting point for medicinal chemistry and further proof that TRPV6 inhibition deserves a place in anti-cancer drug development, while selectivity work remains ahead.
Catalog record
| CREATOR | Lixuan Wang, Xin Deng, Ruoyang Hu, Shuguang Tan, Lin Zhang, Mingqiang Rong, Liqing Hu, Xing Feng, Hui Zou, Junbo Wu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |